Trial Profile
An Open Label Multi-part First-in-human Study of Oral LMI070 in Infants With Type 1 Spinal Muscular Atrophy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 27 Apr 2023
Price :
$35
*
At a glance
- Drugs Branaplam (Primary) ; Branaplam (Primary) ; Branaplam (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; First in man; Proof of concept
- Acronyms CLMI070X2201
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 21 Apr 2023 Status changed from active, no longer recruiting to completed.
- 28 Jan 2023 This trial has been Completed in Poland,(Global end date: 29 Dec 2022) according to European Clinical Trials Database record.
- 25 Jan 2023 This trial has been completed in Germany (End Date: 29 Dec 2022) according to European Clinical Trials Database record.